ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
Status:
Withdrawn
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of an investigational drug
called DMXAA (5-6-dimethylxanthenone-4-acetic acid) or ASA404 when given together with
carboplatin, paclitaxel and cetuximab to treat patients with refractory solid tumors.